#CSL_Behring
LightNews LightNews
newsen.bsky.social
CSL Behring Appoints Edward Wright as New Japan CEO on October 19, 2026#Japan#Tokyo#CSL_Behring#Edward_Wright
CSL Behring Appoints Edward Wright as New Japan CEO on October 19, 2026
Edward Wright, with over 20 years of experience in the pharmaceutical industry, will lead CSL Behring Japan starting October 19, 2026.
third-news.com
October 1, 2026 at 2:23 AM
newsen.bsky.social
CSL Behring Supports Kumamoto Earthquake Victims with Donation and Matching Gift Program#Japan#Tokyo#CSL_Behring#Japan_Red_Cross#Kumamoto_Earthquake
CSL Behring Supports Kumamoto Earthquake Victims with Donation and Matching Gift Program
CSL Behring continues its commitment to support Kumamoto earthquake victims by donating 1 million yen through the Red Cross and matching employee contributions.
third-news.com
August 6, 2026 at 2:59 AM
newsen.bsky.social
CSL Behring Launches Campaign to Raise Awareness for HAE on HAE Day 2023#Japan#Tokyo#CSL_Behring#Hereditary_Angioedema#HAE_Day
CSL Behring Launches Campaign to Raise Awareness for HAE on HAE Day 2023
In honor of HAE Day 2023, CSL Behring conducted various initiatives to enhance awareness and understanding of Hereditary Angioedema, a rare disease.
third-news.com
May 15, 2026 at 6:22 AM
newsen.bsky.social
CSL Behring Launches Awareness Campaign Ahead of World Hemophilia Day#Japan#Tokyo#Hemophilia#CSL_Behring#RARE_LiNK_PROJECT
CSL Behring Launches Awareness Campaign Ahead of World Hemophilia Day
CSL Behring is initiating an awareness campaign in support of World Hemophilia Day, focusing on patient and healthcare collaboration through shared decision-making.
third-news.com
April 13, 2026 at 2:24 AM
newsen.bsky.social
CSL Behring Supports Rare Disease Day 2026 with Special Initiatives#Japan#Rare_Disease_Day#CSL_Behring#Minato,_Tokyo#RARE_LiNK_PROJECT
CSL Behring Supports Rare Disease Day 2026 with Special Initiatives
CSL Behring participates as a diamond sponsor for Rare Disease Day 2026, promoting awareness through a special radio program.
third-news.com
January 29, 2026 at 4:33 AM
newsen.bsky.social
CSL Behring Joins Santa Parade 2025 to Support Children Battling Illness#Japan#Tokyo#community_support#CSL_Behring#Santa_Parade
CSL Behring Joins Santa Parade 2025 to Support Children Battling Illness
CSL Behring participates in the Santa Parade 2025 to support children fighting illnesses and forge community connections. Join us in this noble cause!
third-news.com
December 9, 2025 at 2:50 AM
newsen.bsky.social
CSL Behring Wins Prestigious 2025 ISPE Facility of the Year Award for Innovative Project Aurora#United_States#Charlotte#CSL_Behring#Project_Aurora#ISPE_FOYA
CSL Behring Wins Prestigious 2025 ISPE Facility of the Year Award for Innovative Project Aurora
CSL Behring celebrates winning the 2025 ISPE Facility of the Year Award for its groundbreaking Project Aurora, showcasing innovation in pharmaceutical manufacturing.
third-news.com
October 27, 2025 at 6:13 PM
newsen.bsky.social
CSL Behring Publishes Archive of HAE Online Public Lecture on Patient Challenges#Japan#Tokyo#HAE#CSL_Behring#Hereditary_Angioedema
CSL Behring Publishes Archive of HAE Online Public Lecture on Patient Challenges
CSL Behring has released an archive of an online public lecture on hereditary angioedema, focusing on patient experiences and challenges. This initiative aims to improve quality of life for HAE patients.
third-news.com
September 11, 2025 at 2:52 AM
newsen.bsky.social
CSL Reports Strong FY2025 Financial Results with Strategic Transformations Ahead#Australia#Melbourne#CSL_Behring#CSL_Limited#CSL_Seqirus
CSL Reports Strong FY2025 Financial Results with Strategic Transformations Ahead
CSL reports a notable increase in net profit for FY2025, driving strategic initiatives to enhance growth. Key plans include a proposed demerger and operational efficiencies.
third-news.com
August 18, 2025 at 11:34 PM
newsen.bsky.social
CSL Behring Initiates RARE LiNK PROJECT to Support Rare Disease Patients#Japan#Tokyo#Rare_Diseases#CSL_Behring#RARE_LiNK
CSL Behring Initiates RARE LiNK PROJECT to Support Rare Disease Patients
CSL Behring launches the RARE LiNK PROJECT, a new initiative to connect and support individuals facing rare diseases, fostering community engagement.
third-news.com
July 28, 2025 at 2:20 AM
newsen.bsky.social
CSL Behring Launches New Gene Therapy Information Site for Patients and Families#Japan#Tokyo#gene_therapy#CSL_Behring#Patient_Education
CSL Behring Launches New Gene Therapy Information Site for Patients and Families
CSL Behring has launched the 'Gene Therapy Portal' to provide essential information on gene therapy for patients and families, promoting better understanding.
third-news.com
July 22, 2025 at 4:08 AM
newsen.bsky.social
CSL Behring's ANDEMBRY® Receives Approval for HAE Treatment in Japan#Japan#Tokyo#HAE#CSL_Behring#ANDEMBRY
CSL Behring's ANDEMBRY® Receives Approval for HAE Treatment in Japan
CSL Behring announces the approval of ANDEMBRY®, a novel treatment for hereditary angioedema, marking a significant advancement in patient care.
third-news.com
February 20, 2025 at 2:47 PM
newsen.bsky.social
European Commission Grants Approval for CSL's ANDEMBRY® as a New Treatment for Hereditary Angioedema#Germany#Garadacimab#Marburg#CSL_Behring#ANDEMBRY
European Commission Grants Approval for CSL's ANDEMBRY® as a New Treatment for Hereditary Angioedema
CSL's ANDEMBRY® is now approved by the European Commission as the first monthly treatment for hereditary angioedema, providing hope for patients.
third-news.com
February 13, 2025 at 12:11 PM
newsen.bsky.social
HEMGENIX® Delivers Sustained Efficacy and Safety for Hemophilia B Therapy Even After Four Years#United_States#King_of_Prussia#HEMGENIX#Hemophilia_B#CSL_Behring
HEMGENIX® Delivers Sustained Efficacy and Safety for Hemophilia B Therapy Even After Four Years
The four-year data reveals HEMGENIX®'s efficacy and safety, showing 94% of hemophilia B patients are free from continuous prophylaxis.
third-news.com
February 7, 2025 at 2:22 PM